tirzepatide made of | C225H348N48O68 | CID 156588324 remote-pharmacy-weight-loss-solutions-cc-oral-drops

The risk climbs

The medication doesnt accumulate beyond steady-state levels regardless of treatment duration

More recently, in December, the FDA approved semaglutide for weight loss in adolescents aged 12 to 17 years with an initial BMI in the 95th percentile for age and sex

For tirzepatide, clinical protocols typically use weekly doses ranging from 2.5 mg (starting) to 15 mg (maintenance)

Tirzepatide: Stands out for its dual agonism (GLP-1 and GIP receptors), resulting in substantial weight loss in addition to glycemic control

[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Shetty R., Basheer F.T., Poojari P.G., Thunga G., Chandran V.P., Acharya L.D